Palivizumab immunoprophylaxis for infants with BPD has medium- and long-term benefits: myth or maxim?
| Autor: | Quinn LA; Queens University Belfast School of Medicine Dentistry and Biomedical Sciences, Belfast, UK., Hirani SH; Alder Hey Children's NHS Foundation Trust, Liverpool, UK., Williams TC; Dept of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK.; Department of Child Life and Health, University of Edinburgh, Edinburgh, UK.; Joint senior authors., Sinha IP; Alder Hey Children's NHS Foundation Trust, Liverpool, UK.; Division of Child Health, University of Liverpool, Liverpool, UK.; Joint senior authors. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Breathe (Sheffield, England) [Breathe (Sheff)] 2021 Dec; Vol. 17 (4), pp. 210110. |
| DOI: | 10.1183/20734735.0110-2021 |
| Abstrakt: | It is uncertain whether immunoprophylaxis against RSV protects preterm babies with BPD against future respiratory problems. It is biologically plausible that it does, at least in some infants. https://bit.ly/3ikzwZD. Competing Interests: Conflict of interest: I.P Sinha, S.H. Hirani, and L.A. Quinn have no interests to declare. T.C. Williams sits on the Laboratory Technical Committee for Phase 2 of the WHO Global RSV Surveillance Programme. (Copyright ©ERS 2021.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|